Operator
Welcome to the Braveheart Bio call today. My name is Josh, and I will be your operator for today’s call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Paul Rickey, Chief Financial Officer at Braveheart. Paul, you may begin.
James Rickey
Chief Financial Officer
Thank you, Josh. Good afternoon, and thank you all for joining us. Before we begin, I’d like to remind you that today’s remarks contain forward-looking statements. Please refer to the risk factors in our most recent filings with the SEC for a discussion of the factors that could cause actual results to differ materially from what you will — what we will cover in today’s discussion.
Earlier this afternoon, we, along with our partner, Hengrui, presented data from our BHB-1893 program at the American Heart Association Scientific Sessions 2026. A press release describing these results as well as the presentations themselves are available on our website at braveheart.bio.
With us today, we are pleased to have Dr. Anjali Owens, Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Owens is also Medical Director, Penn Center for Inherited Cardiovascular Disease. Also joining us is Dr. Mariko Harper of Virginia Mason Franciscan Health, where she is the Medical Director of Hypertrophic Cardiomyopathy Center of Excellence. To begin, we’ll have Dr. Travis Murdoch, our Chief Executive Officer and Board Director, share an update.
Credit: Source link
